Zydus Lifesciences has introduced an oral once-a-day therapy, named Rexigo, for testosterone suppression in advanced prostate cancer patients. Priced at Rs 6,995 per month, the medication offers a more cost-effective alternative, being 50% less expensive than current injectable options. The move aims to enhance treatment accessibility, making prostate cancer management in India entirely oral and improving patients’ quality of life. Prostate cancer is a prevalent condition, with over 43,000 cases reported in India in 2022, highlighting the significance of affordable and convenient treatment options.
Zydus Lifesciences Launches Affordable Oral Medication for Advanced Prostate Cancer
![](https://affairsace-media.s3.ap-south-1.amazonaws.com/2024/01/30201648/TNIE_import_2021_9_9_original_Zydus-Cadila-ezgif.com-avif-to-jpg-converter.jpg)